source
- Telix to acquire Germany's ITM for $1.65 billion, aiming to dominate radiopharmaceutical marketTelix, an Australian radiopharmaceutical diagnostics company, announced it will purchase German developer ITM in a cash transaction valued at $1.65 billion upfront. The agreement gives Telix the o…
- Beacon Therapeutics reports successful gene-therapy trial for rare X-linked retinitis pigmentosaBeacon Therapeutics announced that its gene-therapy candidate for X-linked retinitis pigmentosa (XLRP) achieved its primary endpoint in a pivotal trial. The result marks a breakthrough for the rar…